研究论文
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
Yuxiang Ma, Yan Huang, Yuanyuan Zhao, Shen Zhao, Jinhui Xue, Yunpeng Yang, Wen‐Feng Fang, Ye Guo 等 25 位
Sun Yat-sen University Sun Yat-sen University Cancer Center Shanghai East Hospital Hunan Cancer Hospital
来源The Lancet Oncology
年份2024
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
62310
24
6225
26
关键指标
131
被引次数 · OpenAlex
23.38
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 0.3%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
27
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学HER2/EGFR in Cancer Research
Monoclonal and Polyclonal Antibodies Research · Colorectal Cancer Treatments and Studies
参考文献 27
Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis
被引 127Véronique Dièras, Nadia Harbeck, G. Thomas Budd · Journal of Clinical Oncology · 2014
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
被引 114Daniel T. T. Chua, Jonathan S. T. Sham, Gordon K.�H. Au · Oral Oncology · 2003
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
被引 29,868E. Eisenhauer, P. Therasse, Jan Bogaerts · European Journal of Cancer · 2008
此处列出前 3 条
引用本文 131
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
被引 159Fei Zhou, Haoyue Guo, Yang Xia · Nature Reviews Clinical Oncology · 2024
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
被引 116Jacob Sands, Myung‐Ju Ahn, Aaron Lisberg · Journal of Clinical Oncology · 2025
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
被引 91Yuxiang Ma, Yunpeng Yang, Yan Huang · Nature Medicine · 2025
按被引量排序，此处列出前 3 条